{"id":"W4200317891","doi":"10.1038/s41591-021-01538-9","title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Stanford Cancer Institute; National Cancer Institute; Scheme for Promotion of Academic and Research Collaboration; Constellation Pharmaceuticals; National Center for Advancing Translational Sciences; Agios Pharmaceuticals; NIH Blueprint for Neuroscience Research; Astellas Pharma; Gilead Sciences; ARUP Laboratories; Celgene; Sierra Oncology; Incyte; CTI Biopharma; National Heart, Lung, and Blood Institute; Pfizer; Amgen; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Systemic mastocytosis; Medicine; Nausea; Adverse effect; Gastroenterology; Internal medicine; Anemia; Phases of clinical research; Rash; Anaphylaxis; Diarrhea; Clinical trial; Immunology; Allergy; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003744779,0.0001198456,0.0004257773,0.00006531284,0.00005570609,0.000001724098,0.0001097494,0.0002715829,0.0006286158],"category_scores_gemma":[0.0004424828,0.00007158528,0.0000383095,0.0001847456,0.0002421344,0.00002154256,0.00004544055,0.0006348726,0.000007141386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001875722,"about_ca_system_score_gemma":0.000044581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001205763,"about_ca_topic_score_gemma":0.00002601475,"domain_scores_codex":[0.9989972,0.0001709969,0.0003914326,0.0002219293,0.0000509502,0.0001674568],"domain_scores_gemma":[0.9991852,0.0003563132,0.0001146198,0.0002553845,0.00007184569,0.00001665529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04493819,0.0005565862,0.0001302952,0.000208671,0.0001490342,0.0000852554,0.003511267,0.000004508358,0.8942684,0.003472402,0.002637146,0.05003825],"study_design_scores_gemma":[0.5017596,0.002193234,0.002509646,0.001537032,0.0002399615,0.0005436528,0.005569646,0.000007244958,0.09107298,0.00008646386,0.3941701,0.000310406],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9108968,0.08330268,0.0000259533,0.002308138,0.00120482,0.0004348804,0.00002006836,0.00001517498,0.001791489],"genre_scores_gemma":[0.9970928,0.001118038,0.00001840754,0.0002974537,0.0001261681,0.00001472938,0.00009794618,0.000008754722,0.001225719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8031954,"threshold_uncertainty_score":0.6882902,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01102758964833315,"score_gpt":0.2781469277042364,"score_spread":0.2671193380559032,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}